title: Personalized medicine: predicting responses to therapy in patients with RA.
abstract: Personalized medicine where each patient receives the right drug and the right intensity of drug treatment for as long as needed or safe is the goal of medicine. The identification of predictors of response is the first step toward this. In rheumatoid arthritis (RA), several prediction matrices were designed to predict the risk of rapid radiological progression (RRP) in the first year of treatment, on either disease modifying anti-rheumatic drug (DMARD) monotherapy or combination therapy with prednisone or a biological agent. Both clinical markers and biomarkers of response to either anti-TNF or different mode of action biological agents, and of successful discontinuation of these agents once the treatment goal has been achieved, have been identified in different studies. Most of these markers need validation in other cohorts. Research into combining clinical markers and biomarkers of response could lead to identification of risk profiles resulting in a new step toward personalized medicine in RA.
authors.affiliation: Department of Rheumatology, Leiden University Medical Center, The Netherlands. m.van_den_broek@lumc.nl
authors.forename: Marianne
authors.initials: M
authors.lastname: van den Broek
authors.forename: Karen
authors.initials: K
authors.lastname: Visser
authors.forename: Cornelia F
authors.initials: CF
authors.lastname: Allaart
authors.forename: Tom W J
authors.initials: TW
authors.lastname: Huizinga
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001691:Biological Therapy; D006801:Humans; D057285:Precision Medicine; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha